...
首页> 外文期刊>Drug development and industrial pharmacy >Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form.
【24h】

Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form.

机译:在快速分散的卡托普利口服剂型开发过程中评估关键配方因素。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

New methods of manufacture have enabled the creation of novel dosage forms with unique rapid-dispersion properties. This study combines one such technique with a statistical experimental design to develop dosage forms from captopril, an angiotensin-converting enzyme inhibitor used to treat cases of hypertensive emergency. The TheriForm process, a novel microfabrication technique, was used to build the dosage forms in a layer-by-layer fashion. Three key formulation factors were chosen for the design of experiments. A modified central composite design (Box-Behnken design) was used to maximize the efficiency of the experiments. A total of 13 distinct formulations were fabricated and tested, using mannitol as the bulk excipient. In addition, three replicates of the center point were tested to assess variability and experimental error. These formulations were tested for speed of dispersion (flash time), active content, hardness, friability, and moisture absorption. Regression analysis was performed to fit data responses to quadratic equations. Excellent dose accuracy (95% to 102% of target) and content uniformity (between 1.03% to 2.84%) were observed from all experimental formulation batches. As expected, the choice of powder additive (maltitol, maltodextrin, polyvinyl pyrrolidone), level of additive (2.5% to 7.5%), and saturation level of the binder liquid (45% to 65%) were all found to be significant factors for the TheriForm process. The regression analysis suggested that a rapidly dispersing dosage form of optimal physical properties would be obtained when a powder mixture of mannitol (97.5%) and maltitol (2.5%) is used at a saturation level of 45%. In conclusion, rapidly dispersing captopril oral dosage forms were successfully fabricated and tested. A wide range of physical properties, flash time, and hardness, were determined experimentally, and the effects of key formulation factors were identified.
机译:新的制造方法使得能够产生具有独特的快速分散性质的新型剂型。这项研究将一种这样的技术与统计实验设计相结合,从卡托普利开发出剂型,卡托普利是一种用于治疗高血压急症的血管紧张素转化酶抑制剂。 TheriForm工艺是一种新颖的微细加工技术,用于逐层构建剂型。选择了三个关键配方因子进行实验设计。修改后的中央复合设计(Box-Behnken设计)用于最大程度地提高实验效率。使用甘露醇作为主要赋形剂,共制备和测试了13种不同的制剂。另外,测试了中心点的三个重复,以评估变异性和实验误差。测试了这些制剂的分散速度(闪蒸时间),活性成分,硬度,脆性和吸湿性。进行回归分析以使数据响应适合二次方程式。在所有实验配方批次中均观察到极好的剂量准确度(目标的95%至102%)和含量均匀性(1.03%至2.84%之间)。如预期的那样,发现粉末添加剂(麦芽糖醇,麦芽糊精,聚乙烯吡咯烷酮)的选择,添加剂的含量(2.5%至7.5%)和粘合剂液体的饱和度(45%至65%)都是影响生产的重要因素。 TheriForm流程。回归分析表明,当甘露醇(97.5%)和麦芽糖醇(2.5%)的粉末混合物以45%的饱和度使用时,将获得具有最佳物理性能的快速分散剂型。总之,成功制备并测试了快速分散的卡托普利口服剂型。通过实验确定了广泛的物理性能,闪光时间和硬度,并确定了关键配方因素的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号